Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

NIKE

Walmart

I think Walmart can trade to $100 per share easily with 'flywheel' innovation and higher-margin revenue growth, but it will take time, and investors should wait for pullbacks. Merck's Q3 '24 EPS estimate was reduced from $2.22 in the March quarter to $1.81 as of today, while the Q4 '24 EPS estimate was reduced from $2.11 to $1.88, after the 2nd quarter earnings release. The biggest negative I see for Nike is the continued market share gains by HOKA.

Updating Walmart, Merck And Nike Post-Earnings

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA + EV EC Approval.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

AbbVie

These two companies sell products that remain in high demand even during recessions. They also have excellent dividend track records -- and one of them is a Dividend King.

2 Dividend Stocks You Can Safely Hold Through a Recession

Merck's reduced profit guidance is primarily due to recent acquisitions, but the company remains strong with potential for future growth, especially in 2024. Keytruda continues to be a key revenue driver, contributing 45% of Merck's total revenue, with potential for sustained double-digit growth. Strategic acquisitions, like Acceleron, are broadening Merck's pipeline, with new drugs like Winrevair showing promising revenue growth.

Merck's Change To Profit Guidance Provides An Opportunity

In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.

Merck (MRK) Advances But Underperforms Market: Key Facts

MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial failures for the blockbuster drug.

Merck scraps two late-stage trials of cancer drug Keytruda

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the efficacy and safety of oral cladribine for the treatment of generalized Myasthenia Gravis (gMG). Cladribine capsules have the potential to be the first oral treatment for gMG patients. gMG is a rare, neuromuscular disorder causing muscle weakness that can b.

Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.

Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with stereotactic body radiotherapy (SBRT) for the treatment of patients with stage I or II (stage IIB N0, M0) non-small cell lung cancer (NSCLC), including those who are medically inoper.

Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.

MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate

MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.

Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for Certain Patients With Essential Thrombocythemia.

Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia

Costco

Hamilton Beach Brands Hld

New Linde PLC

Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of Distinction are included in this Analyst Blog.

The Zacks Analyst Blog Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of Distinction

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Receives European Commission Approval for WINREVAIR™ (sotatercept).

Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III

Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.

Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

Merck (MRK) Could Be a Great Choice

We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV.

Is Merck Stock A Better Pick Over AbbVie?

Global big pharmaceutical company Merck & Co. Inc. NYSE: MRK shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, but the lowered full-year EPS 2024 guidance sank the stock.

Merck's Stock Dip Offers a Buying Opportunity: Here's Why

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Novo Nordisk

Novartis

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

Raytheon Technologies

TC Energy

Warren Buffett's success stems from evolving his strategy to focus on buying high-quality businesses at fair prices rather than just seeking deep-value investments. By deeply understanding businesses and investing with conviction, Buffett minimizes diversification and adopts an ownership mindset for long-term gains. Applying Buffett's principles, I explore three strong investment opportunities with solid growth potential, emphasizing quality, profitability, and attractive valuations.

Buying Wonderful Businesses At Fair Prices - The Billionaire Way

Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations

Amazon

The Dow Jones has edged higher this year despite concerns about a possible recession. This dynamic favors stocks with a defensive tilt.

News for Merck Stock (MRK)